TriSalus Life Sciences Declares CMS Reimbursement For TriNav Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code
Portfolio Pulse from Benzinga Newsdesk
TriSalus Life Sciences has announced that the Centers for Medicare & Medicaid Services (CMS) will reimburse the TriNav Infusion System, which has been assigned a new Technology Healthcare Common Procedure Coding System (HCPCS) code. This development is significant for the company as it facilitates the adoption of the TriNav Infusion System by healthcare providers by ensuring they can be reimbursed for its use.
December 14, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TriSalus Life Sciences, identified by the symbol TLSI, is likely to experience a positive short-term impact due to CMS's decision to reimburse the TriNav Infusion System, which could lead to increased adoption and revenue.
The assignment of a HCPCS code by CMS for TriSalus's TriNav Infusion System is a critical regulatory milestone that directly impacts the company's product adoption and revenue potential. Reimbursement by CMS is a strong endorsement that can lead to increased use by healthcare providers, as it removes a significant barrier to entry. This news is highly relevant and important for investors in TLSI, as it could lead to increased sales and market penetration. The confidence in this analysis is high due to the direct correlation between CMS reimbursement and healthcare product adoption.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100